{"id":"W4200256437","doi":"10.1016/j.annonc.2021.12.002","title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":262,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Cilag; Pharmacyclics; Takeda Oncology; Chugai Pharmaceutical; Genentech; MorphoSys; Ono Pharmaceutical; Sanofi; Kyowa Hakko Kirin; Astellas Pharma; Celltrion; Eisai; Seagen; Pfizer; Incyte; Astex Pharmaceuticals; Alexion Pharmaceuticals; Regeneron Pharmaceuticals; Daiichi-Sankyo; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; Bayer HealthCare; Celgene; Bristol-Myers Squibb; EUSA Pharma; AstraZeneca; TG Therapeutics; Amgen; Kite Pharma; Meiji Seika Pharma","keywords":"Brentuximab vedotin; Medicine; Oncology; Chemotherapy; Internal medicine; Peripheral T-cell lymphoma; Lymphoma; Peripheral; CD30; Immunology; T cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005393562,0.001581573,0.002239021,0.0003930282,0.000401526,0.001183438,0.001105687,0.001755451,0.003793501],"category_scores_gemma":[0.003544517,0.0005888576,0.002235069,0.0003371744,0.001188715,0.001530173,0.0006301888,0.003044572,0.0006456164],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007746849,"about_ca_system_score_gemma":0.0007637692,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005584238,"about_ca_topic_score_gemma":0.001136514,"domain_scores_codex":[0.9974069,0.001896118,0.000117051,0.0002752531,0.0001454069,0.0001592873],"domain_scores_gemma":[0.9975382,0.000781441,0.000661155,0.0002401382,0.0001447771,0.0006343275],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9885694,0.003117083,0.0008057951,0.0002388725,0.001008436,0.0000227382,0.00002862581,0.0002678329,0.001014207,0.00004875005,0.0003678363,0.004510436],"study_design_scores_gemma":[0.9555534,0.04035256,0.002359791,0.0000222143,0.0006255066,0.00003392779,0.00001595904,0.0002896803,0.0002875335,0.00008692183,0.0003627666,0.000009762502],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873002,0.004687068,0.0007213125,0.0006536651,0.0003776693,0.00293578,0.001568676,0.00007928262,0.001676345],"genre_scores_gemma":[0.9887518,0.001787731,0.001283471,0.0009871899,0.0003927029,0.002572324,0.002122043,0.00002566752,0.002076931],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005393562,"threshold_uncertainty_score":0.02852422,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04146925107950564,"score_gpt":0.3740900802665195,"score_spread":0.3326208291870138,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}